peter attia on semaglutide evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass 184 - [AMA #29 Sneak

The role of interferon- in cardiovascular disease: an update

Purpose-built for physicians Oral semaglutide may prevent heart failure events in certain patients with type 2 diabetes Key takeaways: Compared with placebo, oral semaglutide reduced risk for heart failure events in patients with type 2 diabetes and HF

Pfizer, after discontinuing its initial danuglipron candidate due to safety concerns in April 2025, re-entered the race through a $10 billion acquisition of clinical-stage biotech Metsera in November 2025, securing a next-generation obesity pipeline [43]

Share via: Summary: Peptide Sequencing of GLP-1 Peptide is essential for confirming structure, purity, and modifications in therapeutic peptides

Are GLP-1 agonists suitable for all patients with type 2 diabetes